Capricor Therapeutics has seen its average 12-month analyst price target raised from $23.67 to $27, implying a significant potential upside. The consensus rating remains a 'Buy,' indicating continued analyst confidence despite a mixed distribution of ratings.
The filing discloses that the average 12-month price target for Capricor Therapeutics has been increased by analysts from $23.67 to $27. This update suggests a potential upside of approximately 228% from the November 3, 2026 closing price, which is a strong positive signal for investors. While the consensus rating remains a 'Buy,' it's important to note the distribution of ratings (4 Buys, 6 Holds) among the 10 covering analysts, indicating some divergence in opinion. For traders, this presents a short-term opportunity if the market reacts positively to the increased target, but the long-term implications depend on the company's ability to meet these expectations and convert analyst sentiment into actual performance. A key risk is that the price target is based on future projections, which may not materialize.